| __timestamp | Ionis Pharmaceuticals, Inc. | Iovance Biotherapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 241751000 | 9335772 |
| Thursday, January 1, 2015 | 322292000 | 999000 |
| Friday, January 1, 2016 | 344320000 | 978000 |
| Sunday, January 1, 2017 | 374644000 | 952000 |
| Monday, January 1, 2018 | 1820000 | 956000 |
| Tuesday, January 1, 2019 | 4000000 | 8122999 |
| Wednesday, January 1, 2020 | 12000000 | 8712000 |
| Friday, January 1, 2021 | 11000000 | 13980000 |
| Saturday, January 1, 2022 | 14000000 | 21135000 |
| Sunday, January 1, 2023 | 9133000 | 10755000 |
| Monday, January 1, 2024 | 11215000 |
Cracking the code
In the ever-evolving landscape of biotechnology, understanding cost structures is pivotal. Ionis Pharmaceuticals, Inc. and Iovance Biotherapeutics, Inc. have showcased intriguing trends in their cost of revenue over the past decade. From 2014 to 2023, Ionis Pharmaceuticals experienced a significant fluctuation, with costs peaking in 2017 and then stabilizing to a more sustainable level by 2023. This represents a dramatic reduction of nearly 76% from their 2017 high. Meanwhile, Iovance Biotherapeutics, Inc. has shown a steady increase, with costs rising by over 100% from 2014 to 2023. This growth trajectory highlights Iovance's expanding operational scale and investment in innovation. These insights not only reflect the companies' strategic shifts but also offer a glimpse into the broader biotech industry's financial dynamics. As these companies continue to innovate, their cost management strategies will be crucial in maintaining competitive advantage.
Cost Insights: Breaking Down Sanofi and Ionis Pharmaceuticals, Inc.'s Expenses
Takeda Pharmaceutical Company Limited vs Iovance Biotherapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Comparison: Teva Pharmaceutical Industries Limited vs Iovance Biotherapeutics, Inc.
Cost of Revenue Trends: Neurocrine Biosciences, Inc. vs Ionis Pharmaceuticals, Inc.
Cost Insights: Breaking Down Neurocrine Biosciences, Inc. and Iovance Biotherapeutics, Inc.'s Expenses
Cost Insights: Breaking Down Viatris Inc. and Iovance Biotherapeutics, Inc.'s Expenses
Cost of Revenue Trends: Pharming Group N.V. vs Ionis Pharmaceuticals, Inc.
Comparing Cost of Revenue Efficiency: Ionis Pharmaceuticals, Inc. vs Alkermes plc
Cost of Revenue: Key Insights for Ionis Pharmaceuticals, Inc. and Travere Therapeutics, Inc.
Cost of Revenue: Key Insights for Ionis Pharmaceuticals, Inc. and Viridian Therapeutics, Inc.
Cost of Revenue: Key Insights for Iovance Biotherapeutics, Inc. and Celldex Therapeutics, Inc.
Cost of Revenue: Key Insights for Iovance Biotherapeutics, Inc. and Evotec SE